



GENSIGHT BIOLOGICS



One line pitch:

GenSight Biologics is an early clinical-stage biopharmaceutical company, pioneering the development of gene therapy-based treatments for retinal degenerative diseases.

Market Analysis:

Vision loss & blindness are the most feared consequence of disease apart from death. Ww 40M people are blind and more than 250M people suffer from very low vision (WHO). Visual impairment (VI) & Blindness (B) have considerable impact with direct & indirect costs (loss of well-being, injuries, excess mortality...) Total health care expenditure associated with VI may increase from \$2.30 trillion in 2010 to \$2.77 trillion in 2020. The total productivity loss for the 7 developed subregions increases from \$167 Bn in 2010 to \$176 Bn in 2020. According to Visiongain, ww ophthalmic market was \$17.5 Bn in 2011 & with expected growth up to \$34.7 Bn by 2023, representing a 5.9% CAGR. Retinal degeneration, related to aging (dry-AMD) or genetic (RP), are a major cause of VI with no treatment available.

Business Proposition:

GenSight develops a first replacement therapy of a gene responsible for vision loss in Leber Hereditary Optic Neuropathy (LHON), currently in phase I clinical trial. Another innovative approach is based on optogenetics technology, to make cells sensitive to light by introducing, using viral vectors, photosensitive proteins, in order to restore vision in patients with very low vision or total blindness due to retinitis pigmentosa (RP), with the objective to provide a quality of life and sight associated to a level of vision consistent with a significant improvement of independence. GenSight operates within the field of orphan diseases treatments in order to build a world leader in gene therapy in ophthalmology to provide unique solutions to patients with high unmet medical needs.

Competitive Advantage:

- Founded by top-tier scientists and clinicians from EU and USA and experienced management with successful track record - Establishing strong relationships with the Ophtha community and patient centric approach with Orphan diseases - Leading two lead projects addressing unmet medical needs with potential early access

Investment Attractiveness:

Founded by top-tier scientists and clinicians from EU and USA and experienced management with successful track record, GenSight is leading two lead projects addressing unmet medical needs with potential early access. We are establishing strong relationships with the ophthalmology community and patient centric approach with orphan diseases to ensure early patient access and commercial product success.

IP Situation:

GenSight Biologics projects and strategy are based on a solid IP portfolio. The company has secured exclusive and worldwide rights for targeting mitochondrial mRNA from the nucleus of the cells to the surface of the mitochondrion and for optogenetic approaches. In addition, patents are being filed in technologies around biomimetic visual interface.

COMPANY PROFILE

- **Website:**
www.gensight-biologics.com
- **Activity:** Biotech
- **Contact:**
Scarabin Isabelle
iscarabin@gensight-biologics.com
- **Location:**
89 rue du Fbg St Antoine
Gensight Biologics
75011 Paris
France
- **Founded in:** 21/03/2013
- **Employees:** 11
- **Management:**
Pruneau Didier
CSO
Thomasson Nitza
Chief Preclinical Operation
Officer
Combal Jean Philippe
COO
Gilly Bernard
CEO
- **Financial information (€):**
 - **Company stage:**
clinical stage company
 - **Capital raised to date:**
35 M
 - **Monthly burn rate:**
 - **Capital seeking and date:**
- **Investors:**
Abingworth, Novartis Venture Fund, Versant Ventures, Index Ventures, French Rare Diseases seed Fund
- **Referred by:**
BIOVISION